New immunohistochemical method for improved myotonia and chloride channel mutation diagnostics

12Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Objective: The objective of this study was to validate the immunohistochemical assay for the diagnosis of nondystrophic myotonia and to provide full clarification of clinical disease to patients in whom basic genetic testing has failed to do so. Methods: An immunohistochemical assay of sarcolemmal chloride channel abundance using 2 different ClC1-specific antibodies. Results: This method led to the identification of new mutations, to the reclassification of W118G in CLCN1 as a moderately pathogenic mutation, and to confirmation of recessive (Becker) myotonia congenita in cases when only one recessive CLCN1 mutation had been identified by genetic testing. Conclusions: We have developed a robust immunohistochemical assay that can detect loss of sarcolemmal ClC-1 protein on muscle sections. This in combination with gene sequencing is a powerful approach to achieving a final diagnosis of nondystrophic myotonia. © 2012 American Academy of Neurology.

Cite

CITATION STYLE

APA

Raheem, O., Penttilä, S., Suominen, T., Kaakinen, M., Burge, J., Haworth, A., … Udd, B. (2012). New immunohistochemical method for improved myotonia and chloride channel mutation diagnostics. Neurology, 79(22), 2194–2200. https://doi.org/10.1212/WNL.0b013e31827595e2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free